Rajesh Mohandas, MD
Nephrology · New Orleans, LANPI 1275642837
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,369, more than ten times the $100 reported in 2019.
Across 100 payments — averaging $36.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$715
- Otsuka Pharmaceutical Development & Commercialization, Inc.$359
- GSK$265
- Otsuka America Pharmaceutical, Inc.$228
- Fresenius USA Marketing, Inc.$216
- Mallinckrodt Hospital Products Inc.$211
- plus $2K from 16 others
Across 25 payments — averaging $3141.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$59K
- Vertex$19K
- Boehringer Ingelheim International GmbH$266
What the payments were for
- Food & beverage$3,43595%
- Education$1995%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $715 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $359 |
| GSK | 5 | $265 |
| Otsuka America Pharmaceutical, Inc. | 11 | $228 |
| Fresenius USA Marketing, Inc. | 2 | $216 |
| Mallinckrodt Hospital Products Inc. | 7 | $211 |
| Vifor Pharma, Inc. | 6 | $205 |
| Aurinia Pharma U.S., Inc. | 7 | $172 |
| Novartis | 5 | $160 |
| Calliditas Therapeutics US Inc. | 6 | $146 |
| AstraZeneca(2 entities) | 3 | $138 |
| Bayer | 7 | $131 |
| Vantive US Healthcare LLC | 1 | $118 |
| Travere Therapeutics, Inc. | 5 | $114 |
| Akebia Therapeutics Inc | 4 | $106 |
| Mallinckrodt Enterprises LLC | 1 | $100 |
| Idorsia Pharmaceuticals US Inc | 1 | $99 |
| Nxstage Medical, Inc. | 1 | $49 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Argenx US, Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,633 in reported general payments places this provider in the 65th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Chlorthalidone | 18 | $168 |
| Amlodipine Besylate | 12 | $111 |
| ClopidogrelClopidogrel Bisulfate | 13 | $82 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New Orleans
- Juan Carlos VelezNew Orleans$282K
- Michael TouchyNew Orleans$56K
- Juan MedauraNew Orleans$14K
- Farshid YazdiNew Orleans$14K
- Mihran NaljayanNew Orleans$10K
- Rhea BhargavaNew Orleans$9K
- April FoxNew Orleans$8K
- Myra KleinpeterNew Orleans$7K
- Joshua LowentrittNew Orleans$7K
- Angela ReginelliNew Orleans$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.